Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03387462 · ClinicalTrials.gov registry record · Phase 4

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

A Phase 4 study of HIV Prevention and Adherence, Medication, sponsored by Public Health Foundation Enterprises.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
2
Study locations

NCT03387462 is a Phase 4 study of HIV Prevention and Adherence, Medication that has completed, run by Public Health Foundation Enterprises. The registered enrollment target is 20 participants, below the 381-participant average among 32 other HIV Prevention trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03387462, a Phase 4 study of HIV Prevention and Adherence, Medication, has completed, sponsored by Public Health Foundation Enterprises.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is time to take their medication, and uses motion-sensing technology to visually and automatically confirm the pill was swallowed. The goal of this study is to understand people's experiences using this new app while taking HIV pre-exposure prophylaxis (PrEP) for the prevention of HIV.

Conditions Studied

HIV Prevention Adherence, Medication Pre-exposure Prophylaxis Risk Behavior

Interventions

  • DRUG Emtricitabine / Tenofovir Disoproxil Oral Tablet
  • OTHER DOT Diary mobile app

Study Locations (2)

California

  • Bridge HIV, San Francisco Department of Public Health - San Francisco

Georgia

  • Emory University, School of Public Health - Atlanta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-02-28
Est. Completion 2018-08-30
Phase Phase 4

Sponsor

Public Health Foundation Enterprises

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03387462

The ClinicalTrials.gov registry entry for NCT03387462 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 32 other HIV Prevention trials with a reported enrollment target (95% lower). The listed sponsor is Public Health Foundation Enterprises, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with HIV Prevention appearing as the primary indexed condition, and to 2 interventions - of which Emtricitabine / Tenofovir Disoproxil Oral Tablet is the first listed.

NCT03387462 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03387462 about?

NCT03387462 is a clinical study titled "DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence". The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is time to take their medication, and uses motion-sensing technology to visually and automatically confirm the pill wa...

What is the current status of trial NCT03387462?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2018-02-28. Estimated completion is 2018-08-30.

What conditions does trial NCT03387462 study?

This clinical trial studies the following conditions: HIV Prevention, Adherence, Medication, Pre-exposure Prophylaxis, Risk Behavior.

What interventions are being tested in trial NCT03387462?

The interventions under investigation include: Emtricitabine / Tenofovir Disoproxil Oral Tablet (DRUG), DOT Diary mobile app (OTHER).

Who is sponsoring clinical trial NCT03387462?

This trial is sponsored by Public Health Foundation Enterprises, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03387462 being conducted?

This trial has 2 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Prevention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Prevention

All registered trials for this condition

Adherence, Medication

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.